JP2022500081A5 - - Google Patents
Info
- Publication number
- JP2022500081A5 JP2022500081A5 JP2021538178A JP2021538178A JP2022500081A5 JP 2022500081 A5 JP2022500081 A5 JP 2022500081A5 JP 2021538178 A JP2021538178 A JP 2021538178A JP 2021538178 A JP2021538178 A JP 2021538178A JP 2022500081 A5 JP2022500081 A5 JP 2022500081A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729458P | 2018-09-11 | 2018-09-11 | |
| US62/729,458 | 2018-09-11 | ||
| PCT/US2019/050575 WO2020055975A1 (en) | 2018-09-11 | 2019-09-11 | Anti-trem-2 agonist antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500081A JP2022500081A (ja) | 2022-01-04 |
| JP2022500081A5 true JP2022500081A5 (https=) | 2022-09-20 |
Family
ID=69777153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538178A Pending JP2022500081A (ja) | 2018-09-11 | 2019-09-11 | 抗ｔｒｅｍ−２アゴニスト抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12145988B2 (https=) |
| EP (1) | EP3849598A4 (https=) |
| JP (1) | JP2022500081A (https=) |
| KR (1) | KR20210057113A (https=) |
| CN (1) | CN113164572A (https=) |
| AU (1) | AU2019339452A1 (https=) |
| BR (1) | BR112021004316A2 (https=) |
| CA (1) | CA3111569A1 (https=) |
| IL (1) | IL281201A (https=) |
| MX (1) | MX2021002616A (https=) |
| SG (1) | SG11202102162RA (https=) |
| WO (1) | WO2020055975A1 (https=) |
| ZA (1) | ZA202101537B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2023192282A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| CA3254085A1 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women's Hospital, Inc. | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024160736A1 (en) * | 2023-01-30 | 2024-08-08 | Isar Bioscience Gmbh | Human anti-trem2 antibody for treating neurodegenerative disorders |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US20150140672A1 (en) | 2011-12-19 | 2015-05-21 | Washington University | Methods for detecting amyloid beta amyloidosis |
| AU2012359020B2 (en) | 2011-12-19 | 2017-04-13 | The Washington University | Methods for diagnosing Alzheimer's disease |
| EP2923209A4 (en) | 2012-11-20 | 2016-04-27 | Univ Washington | METHOD FOR THE DIAGNOSIS OF DISEASES BY ANALYSIS OF AMYLOID BETA ENRICHMENT KINETICS |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2016064895A1 (en) * | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CN109641961A (zh) * | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
-
2019
- 2019-09-11 CA CA3111569A patent/CA3111569A1/en active Pending
- 2019-09-11 WO PCT/US2019/050575 patent/WO2020055975A1/en not_active Ceased
- 2019-09-11 JP JP2021538178A patent/JP2022500081A/ja active Pending
- 2019-09-11 SG SG11202102162RA patent/SG11202102162RA/en unknown
- 2019-09-11 EP EP19860614.7A patent/EP3849598A4/en not_active Withdrawn
- 2019-09-11 BR BR112021004316A patent/BR112021004316A2/pt not_active Application Discontinuation
- 2019-09-11 AU AU2019339452A patent/AU2019339452A1/en not_active Abandoned
- 2019-09-11 KR KR1020217010551A patent/KR20210057113A/ko not_active Withdrawn
- 2019-09-11 MX MX2021002616A patent/MX2021002616A/es unknown
- 2019-09-11 CN CN201980074318.5A patent/CN113164572A/zh active Pending
- 2019-09-11 US US17/275,092 patent/US12145988B2/en active Active
-
2021
- 2021-03-02 IL IL281201A patent/IL281201A/en unknown
- 2021-03-05 ZA ZA2021/01537A patent/ZA202101537B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500081A5 (https=) | ||
| JP2020506162A5 (https=) | ||
| US12503501B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | |
| AU2024216537A1 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| ES2902467T3 (es) | TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento | |
| Afridi et al. | New onset migraine with a brain stem cavernous angioma | |
| Prasetyo | The primary, secondary, and tertiary brain injury | |
| Shivakumar et al. | Do schizophrenia patients age early? | |
| US20190328782A1 (en) | Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products | |
| JP2020506162A (ja) | 抗ａｐｏｅ抗体 | |
| US12084491B2 (en) | Treatment of Parkinson's disease | |
| WO2020018343A1 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| Kase et al. | Shotgun pellet embolus to the middle cerebral artery | |
| García-Cazorla et al. | White matter alterations associated with chromosomal disorders | |
| JPWO2002076492A1 (ja) | 新規な運動障害改善剤 | |
| RU2021109803A (ru) | Антитела-агонисты trem-2 | |
| AU2021331859A1 (en) | Peptide composition for prevention or treatment of Alzheimer's disease | |
| Watanabe et al. | Steroid-responsive limbic encephalitis | |
| Keith et al. | Neuropathological homology in true Galloway-Mowat syndrome | |
| US20250127734A1 (en) | Alz-801 for use in treating a covid-19 associated neurological symptom | |
| Croisile | Benson’s syndrome or posterior cortical atrophy | |
| JP7299304B2 (ja) | 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドｇｈｒｐ６とを含む薬学的組合せ | |
| US20190038613A1 (en) | Combination therapy | |
| Kanuri et al. | Posterior Reversible Encephalopathy Syndrome (PRES): Deceptive Facade than Meets the Eye | |
| Sabau et al. | Hypoparathyroidism diagnosed by neurological signs and widespread intracerebral calcifications |